Simponi aria skin#

For members who have previously received a biologic or targeted synthetic DMARD (e.g.

Moderately to severely active rheumatoid arthritis (RA).

Simponi aria skin#

Intravenous golimumab (Simponi Aria)Īetna considers intravenously administered golimumab (Simponi Aria) medically necessary for the following indications, where the member has had a documented negative TB test (which can include a tuberculosis skin test (PPD), an interferon-release assay (IGRA), or a chest x-ray) Footnote1* within 6 months of initiating therapy for persons who are naive to biologic DMARDs or targeted synthetic DMARDs associated with an increased risk of TB: For information on site of service for Simponi Aria infusions, see Utilization Management Policy on Site of Care for Specialty Drug Infusions. Note: Site of Care Utilization Management Policy applies to Simponi Aria. Medicare Part B plans: Precertification of intravenous golimumab (Simponi Aria) is required of participating providers and members in applicable Medicare Part B plan designs. Note: Simponi Aria (golimumab intravenous) requires precertification:Ĭommercial plans: Precertification of intravenous golimumab (Simponi Aria) is required of all Aetna participating providers and members in applicable plan designs.